519 related articles for article (PubMed ID: 29139039)
21. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
22. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
24. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
Song Z; Wang X; Zheng Y; Su H; Zhang Y
Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
[TBL] [Abstract][Full Text] [Related]
25. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
26. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
27. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
29. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
30. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
31. Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.
Lapère C; Cortot AB; Grégoire V; Cockenpot V; Tulasne D; Copin MC
Am J Surg Pathol; 2017 Mar; 41(3):414-422. PubMed ID: 28098570
[TBL] [Abstract][Full Text] [Related]
32. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
33. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
34. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
[TBL] [Abstract][Full Text] [Related]
35. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
[TBL] [Abstract][Full Text] [Related]
36. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.
Castiglione R; Alidousty C; Holz B; Wagener S; Baar T; Heydt C; Binot E; Zupp S; Kron A; Wolf J; Merkelbach-Bruse S; Reinhardt HC; Buettner R; Schultheis AM
Mod Pathol; 2019 May; 32(5):627-638. PubMed ID: 30459450
[TBL] [Abstract][Full Text] [Related]
38. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.
Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F
Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755
[TBL] [Abstract][Full Text] [Related]
39. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
Dziadziuszko R; Wynes MW; Singh S; Asuncion BR; Ranger-Moore J; Konopa K; Rzyman W; Szostakiewicz B; Jassem J; Hirsch FR
J Thorac Oncol; 2012 Feb; 7(2):340-7. PubMed ID: 22237262
[TBL] [Abstract][Full Text] [Related]
40. Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations.
Hayashi T; Kohsaka S; Takamochi K; Kishikawa S; Ikarashi D; Sano K; Hara K; Onagi H; Suehara Y; Takahashi F; Saito T; Nakatsura T; Kitano S; Suzuki K; Yao T
Histopathology; 2021 Jun; 78(7):987-999. PubMed ID: 33249657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
